Table II. Mutations in VH3-23-Cγ... | Rockefeller University Press

Table II.

Mutations in VH3-23-Cγ transcripts from PBL from ATRD patients and controls^{^a}

		Clones					Mutations in V region
	Age (yr)	All	Distinct	Unmutated	Total	% bp	CDR/FR^{^b}	CDRs	FRs
ATRD patients
ATRD1	25	15	13	0	302	8.6	0.73	3.4	1.8
ATRD2	13	15	14	2	258	6.8	0.73	3.7	1.7
ATRD3	15	6	6	0	194	11.9	0.62	3.9	2.0
Total		36	33	2	754	8.4	0.70	3.6	1.8
Controls
C1	14	12	11	1	100	3.4	1.22	5.9	1.5
C2	adult	11	11	0	275	9.3	0.73	4.5	1.7
C3	28	6	6	0	147	9.0	0.69	5.7	2.0
C4	24	8	8	0	178	8.2	0.51	14.0	2.2
C5	30	4	4	0	49	4.5	0.53	^{^c}	1.1
Total		41	40	1	749	6.9	0.70	6.2	1.8

		Clones					Mutations in V region
	Age (yr)	All	Distinct	Unmutated	Total	% bp	CDR/FR^{^b}	CDRs	FRs
ATRD patients
ATRD1	25	15	13	0	302	8.6	0.73	3.4	1.8
ATRD2	13	15	14	2	258	6.8	0.73	3.7	1.7
ATRD3	15	6	6	0	194	11.9	0.62	3.9	2.0
Total		36	33	2	754	8.4	0.70	3.6	1.8
Controls
C1	14	12	11	1	100	3.4	1.22	5.9	1.5
C2	adult	11	11	0	275	9.3	0.73	4.5	1.7
C3	28	6	6	0	147	9.0	0.69	5.7	2.0
C4	24	8	8	0	178	8.2	0.51	14.0	2.2
C5	30	4	4	0	49	4.5	0.53	^{^c}	1.1
Total		41	40	1	749	6.9	0.70	6.2	1.8

Total RNA was prepared from PBL from all the patients and controls, except for donor C2; buffycoat was obtained and CD27 positive B cells were used.

FR, framework region.

Too few mutations to give a reliable ratio.